Features
As technological advances sweep the pharmaceutical industry, this issue explores C&Q digitalization to ensure alignment with current practices.
In today’s pharmaceutical landscape, speed, compliance, and efficiency are no longer optional—they’re strategic imperatives. Yet for large capital expenditure (CapEx) projects, traditional paper-based commissioning, qualification, and validation (CQV) workflows remain a major bottleneck, consuming time, resources, and patience.
Radiopharmaceuticals account for many lifesaving diagnostic and therapeutic drug products in the market. These drug products, radioligand therapies (RLTs) in particular, represent a relatively novel modality and present multiple, unique challenges to manufacture, release, ship, and administer.
ASTM E2500, issued in 2007, has been the primary standard guide defining what is required to apply quality risk management (QRM) to achieve the qualification of facilities, systems, and equipment in support of validation and process validation. A major update was undertaken in 2024 to better align the guide with current regulatory and industry guidance and current best practice.
Schedule management faces challenges such as unrealistic deadlines, scope creep, resource constraints, and poor communication, often causing delays and cost overruns. Using tools like an interdependency matrix (IDM) with project management software tools like Microsoft Project improves accuracy, visibility, and control.
This article provides guidance on the best practices to adopt when preparing for an audit or inspection, with a particular focus on commissioning and qualification and the points to consider during the development of materials to explain a company’s individual approach to commissioning, qualification, and validation maintenance.
Since the US Food and Drug Administration (FDA) introduced the requirement for secure, computer-generated, time-stamped audit trails in 21 CFR Part 11, audit trail functionality has been recognized as a critical component of data integrity.
The COVID-19 pandemic revealed how unprepared the vaccine industry was for such a global health emergency, but also how the industry rose to meet this challenge. The first efficient COVID-19 vaccines approved were based on a new class of vaccines using messenger ribonucleic acid (mRNA) technology.
As facilities become more complex and equipment requirements more demanding, engineers face increasing challenges in ensuring optimal airflow patterns. Fortunately, advanced digital tools such as computational fluid dynamics (CFD) and building information modeling (BIM) are revolutionizing the way cleanrooms are engineered.
Qualification of equipment used in the manufacturing of pharmaceutical products is a critical step in ensuring the production of a product that consistently meets all critical quality attributes. The US Food and Drug Administration (FDA) has stated a shelf temperature mapping, or a shelf temperature uniformity study is an expected step in the qualification of lyophilizers (freeze dryers).
What if your next digital investment did not deliver the transformation you expected? For many pharmaceutical companies, that is the reality.
The rapid rise of cellular therapies is transforming modern medicine and creating new challenges for manufacturers. Unlike traditional biopharmaceuticals, cell-based products demand innovative approaches to aseptic processing, process closure, automation, and scalability.
Chip Bennett, Senior Director at Project Farma, is a Project Management Institute®–certified Project Management Professional (PMP), recognized industry expert, speaker, and published author. He is a consultant with more than 25 years of experience in the pharmaceutical and regulated non-pharmaceutical industries and has expertise in risk-based commissioning and qualification...
Stephanie White is a pharmaceutical and biotechnology manufacturing leader with more than 23 years of experience helping teams turn high-stakes projects into confident, inspection-ready operations. She now serves as a Commissioning, Qualification, and Validation (CQV) and Operational Readiness Lead at A-Bio, a consulting firm, supporting sterile manufacturing and complex capital programs. Her...
Categorization offers a useful starting point for assessing the risk of failure for individual software components, but it is not a validation checklist. Organizations must apply critical thinking to combine categorization with risk assessment and supplier assessments to appropriately scale life cycle activities and manage risk.
This article presents a model for promoting data quality of real-world data and evidence (RWD/RWE) and GxP processes with references to ISO 8000 for data quality management, making it a common language between regulated and nonregulated organizations.
Data integrity drives quality and compliance. Content addressable storage (CAS) stores and retrieves files by content type—not file location—using cryptographic fingerprints. The result: a mathematically provable version control, without broken links and far fewer audit headaches.
Sustainability principles can be effectively integrated into commissioning and qualification (C&Q) projects to support environmental goals without compromising compliance, quality, or patient safety. By positioning C&Q as both a verification tool and an enabler of sustainable intent, this article outlines a practical path for the pharmaceutical sector to enhance operational efficiency,...
The pharmaceutical industry’s embrace of digital technologies and sustainability is no longer a competitive advantage, but an operational necessity. As Pharma 4.0™ matures, its integration will be vital for achieving net-zero objectives and achieving pharmaceutical excellence.
Crafting a sustainable packaging strategy for the pharmaceutical industry is complex and requires balancing environmental responsibility with regulatory compliance and operational costs. In this article, we explore the key drivers, challenges, and best practices for developing such a strategy.
The development of platform drug delivery devices for combination products offers a transformative approach to drug delivery by enabling the reuse of device data across multiple drug and device combinations.
Currently, there is no single guidance document providing a comprehensive roadmap for executing digital validation. While elements from ISPE GAMP® Guides Series and the ISPE Baseline® Guide: Volume 8 – Pharma 4.0™, apply to digital validation, there is no consolidated resource addressing common questions. The authors of this Concept Paper therefore advocate for the development of a Good...
The ISPE Mid-Atlantic Science and Technology Showcase (MAST) in Baltimore, Maryland, USA held on 7 May highlighted the strength, technical capability, and collaborative spirit of the life sciences industry. Hosted by the ISPE Chesapeake Bay Area Chapter at M&T Bank Stadium, the show brought together more than 950 registrants from across the pharmaceutical and biotechnology community for a...
The Facility of the Year Awards (FOYA) Category Winners announcement was once again a cornerstone moment of the 2026 ISPE Europe Annual Conference in Copenhagen, Denmark, offering attendees an inside look at the facilities that were shaping the future of...
As a fitting conclusion to the 2026 ISPE Europe Annual Conference, 30 conference attendees took the opportunity to step inside one of the industry’s most advanced biologics manufacturing facilities during a sold out tour of the FUJIFILM Biotechnologies site in Hillerød, Denmark. Held on Thursday, 23 April, the sold-out tour offered attendees an in depth look at how large scale biologics...
ISPE’s upcoming 2026 ISPE AI in Life Sciences Summit – Powered by GAMP®, taking place 23–24 June in Boston, Massachusetts, will bring together a diverse group of professionals from across the pharmaceutical and tech industry to address the nascent opportunities and challenges for applying artificial intelligence in the...
For those considering joining ISPE, there’s never been a better moment. For a limited time, new and renewing ISPE members can access a free GAMP® microlearning course—an exclusive offer designed to strengthen foundational knowledge in pharmaceutical manufacturing and regulatory compliance.
The current upstream process, particularly the synthesis step, that has been widely used in the industry, is the Solid Phase Oligonucleotide Synthesis (SPOS). While SPOS remains functional for many companies, it is increasingly perceived as being at the brink of capacity limits, especially in light of the projected increases in demand.
Artificial intelligence is no longer a future concept for the pharmaceutical industry—it’s actively reshaping how quality, manufacturing, and regulatory compliance are managed today. In the latest episode of the
The life sciences industry is undergoing a profound digital transformation, driven by the convergence of artificial intelligence (AI), cloud computing, and advanced analytics. These technologies are reshaping how organizations manage quality across the product lifecycle from development and manufacturing to post-market surveillance.
As artificial intelligence (AI) continues to accelerate across the life sciences industry, leaders face a critical question: how do we adopt AI at scale without compromising patient safety, data integrity, or regulatory compliance? The 2026 ISPE AI in Life...
The rational and regulated application of LLMs in GMP biotech IT compliance work can effectively eliminate the risks of information disclosure.
Careers in pharmaceutical and biopharmaceutical manufacturing are rarely linear. They evolve across technical disciplines, leadership roles, and life stages—and the professionals who thrive are often those with a steady anchor. For Lindsey Daniel, PE, Head of Global Operational Excellence, Biologics, at Takeda, that anchor has been ISPE.
Attending industry conferences is often associated with technical sessions and formal presentations, but meaningful insights can also emerge beyond these sessions. This testimonial, written by Khushi Dhingani, offers an observational look at the 2026 ISPE...
The pharmaceutical industry is undergoing one of the most intense periods of transformation in its history. Advances in science, the acceleration of digital technologies, evolving regulatory expectations, and mounting sustainability pressures are reshaping how medicines are developed and manufactured. Against this backdrop, the
The life sciences and diagnostics industry are undergoing a transformative digital evolution. Laboratory systems, electronic lab notebooks (ELN), TrackWise Digital (TWD), and enterprise content management platforms like Livelink are increasingly integrated with clinical, quality, and operational workflows. These technologies improve efficiency, traceability, and operational scalability, but...
Some people contribute to an industry. Others help define it. Jack Lysfjord did the latter.
From 20–22 April 2026, the 2026 ISPE Europe Annual Conference will bring pharmaceutical and biopharmaceutical professionals to Copenhagen, Denmark, for three days of focused discussion on the challenges shaping the future of regulated manufacturing. As...
The GAMP® South Asia Community of Practice (CoP) convened on 5 February 2026 to explore one of the most important topics facing the life sciences today: how to build and use trustworthy AI, kindly hosted by the ISPE Philippines Affiliate. This virtual event brought together professionals across the region—many already experimenting with AI, others just beginning their journey—for an...
Sponsored content is the sole responsibility of the authors and is not endorsed, reviewed, nor a published article of Pharmaceutical Engineering® magazine or ISPE.
Pharmaceutical manufacturing is nearly 50% more emissions intensive per dollar of revenue than the automotive sector. Yet for some medicines, up to 95% of emissions occur upstream, in raw material sourcing and production, long before a product reaches a patient. At the same time, confidence is eroding. In 2024, four in ten executives reported uncertainty about whether sustainability...
Manual testing of Total Organic Carbon (TOC) and conductivity, both required for compendial water quality, is a time-intensive process that can consume hours of analyst time through sample collection, data recording, and LIMS review. To address this inefficiency, a Global Biotechnology Company evaluated a membrane conductometric TOC analyzer capable of simultaneously measuring both parameters...
Whether networking at events or collaborating through our Communities of Practice, the value of an ISPE membership is in the connections made between pharmaceutical industry professionals and Regulators to collaborate on solutions to common goals and challenges.
Are you a subject-matter expert in the global pharmaceutical industry? Are you brimming with knowledge about the latest technical developments or regulatory initiatives? Have you found an innovative solution to a real-world challenge?
Contribute your knowledge and experience to the always-evolving pharmaceutical industry!
Do you know someone whose profile or work should be featured in Pharmaceutical Engineering? Contact ISPE Publications Department.